[Oral administration of beraprost sodium did not exacerbate pulmonary hypertension with CREST syndrome].
Furukawa
K
K
Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.
Ikeda
S
S
Obase
K
K
Muroya
T
T
Oka
H
H
Kojima
M
M
Miyahara
Y
Y
Kohno
S
S
D000368:Aged; D017675:CREST Syndrome / Q000150:complications*; D018450:Disease Progression; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; C048081:beraprost; D011464:Epoprostenol